Status | Study |
Completed |
Study Name: A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Condition: Transfusional Iron Overload Date: 2010-01-05 Interventions: Drug: ICL670 |
Terminated |
Study Name: Clinical Importance of Treating Iron Overload in Sickle Cell Disease Condition: Anemia, Sickle Cell Transfusion Hemosiderosis Date: 2009-09-21 Interventions: Drug: deferasirox Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron conc |
Completed |
Study Name: Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food Condition: Transfusional Hemosiderosis Date: 2009-02-16 Interventions: Drug: deferasirox: deferasirox 20mg/kg/day unless on a higher dose at time of study entry. Crushed or di |
Enrolling by invitation |
Study Name: PHOX2B Mutation-Confirmed Congenital Central Hypoventilation Syndrome in A Chinese Family: Presentations From Newborn to Adulthood Condition: Central Alveolar Hypoventilation Syndrome Date: 2008-04-01 Interventions: Device: CPAP CPAP treatment for patients with congenital central hypoventilation syndrome |
Completed |
Study Name: Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis Condition: Chronic Anemia Transfusional Hemosiderosis Date: 2008-02-27 Interventions: Drug: Deferasirox (ICL670) The recommended initial daily dose of Deferasirox is 20 mg/kg body weight. |
Completed |
Study Name: Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload Condition: Transfusional Iron Overload Transfusional Hemosiderosis Date: 2008-01-14 Interventions: Drug: Core Study: Deferasirox |
Completed |
Study Name: Safety, Tolerability, and Efficacy of Deferasirox in MDS Condition: Myelodysplastic Syndromes Hemosiderosis Date: 2007-05-03 Interventions: Drug: Deferasirox |
Completed |
Study Name: ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox Condition: Anemia Date: 2007-04-25 Interventions: Drug: Deferasirox |
Completed |
Study Name: Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients Condition: Anemia Hemosiderosis Date: 2005-10-14 Interventions: Drug: Deferasirox Deferasirox available as 125 mg, 250 mg or 500 mg tablets |
Completed |
Study Name: A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis Condition: Beta-Thalassemia Hemosiderosis Date: 2005-09-12 Interventions: Drug: deferasirox |